BlackRock’s Context Therapeutics CNTX Stock Holding History

BlackRock’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.42M	Buy	6,169,250 +5,322,554	+629%	+$10.8M	﹤0.01%	4022
2026 Q1	$2.22M	Sell	846,696 -1,350	-0.2%	-$3.15K	﹤0.01%	4113
2025 Q4	$1.25M	Sell	848,046 -924	-0.1%	-$1.08K	﹤0.01%	4241
2025 Q3	$822K	Hold	848,970	–	–	﹤0.01%	4344
2025 Q2	$556K	Hold	848,970	–	–	﹤0.01%	4413
2025 Q1	$520K	Sell	848,970 -63,435	-7%	-$55.2K	﹤0.01%	4385
2024 Q4	$958K	Buy	912,405 +63,435	+7%	+$110K	﹤0.01%	4232
2024 Q3	$1.66M	Sell	848,970 -2,726	-0.3%	-$6.05K	﹤0.01%	4052
2024 Q2	$1.71M	Buy	+851,696	New	+$1.47M	﹤0.01%	4010
2022 Q2	–	Sell	-16,961	Closed	-$37K	–	5867
2022 Q1	$37K	Buy	16,961 +5,414	+47%	+$11.4K	﹤0.01%	5472
2021 Q4	$31K	Buy	+11,547	New	+$57.6K	﹤0.01%	5487

Other funds holding CNTX

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlackRock's CNTX Position: Q2 2026 in Review

BlackRock increased its Context Therapeutics (CNTX) stake by 629% in Q2 2026, buying an estimated $10.8M and bringing the position to 6,169,250 shares worth $3.42M. The position accounts for ﹤0.01% of the portfolio, ranked #4022.

BlackRock first reported a position in CNTX in Q4 2021 and has held it in 11 quarters since. 43 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

BlackRock held 6,169,250 shares of Context Therapeutics worth $3.42M as of Q2 2026.
BlackRock bought 5,322,554 Context Therapeutics shares in Q2 2026, an estimated $10.8M.
Context Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4022 holding.
BlackRock first reported a position in Context Therapeutics in Q4 2021 and has held it in 11 quarters since.
43 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.